Approval · Notice of Compliance 10936 · 2010
REVATIO: Notice of Compliance 10936
Issued January 14, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10936
- Date
- January 14, 2010
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosage form: solution for injection
- Therapeutic class
- cGMP-specific phosphodiesterase type 5 inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REVATIO | 02341611 | Marketed |
Medicinal ingredients
- SILDENAFIL CITRATE 0.8 MG per ML